TCT 2019: Abbott’s Portico TAVR Crosses Non-Inferiority Threshold
Abbott’s Portico transcatheter aortic valve performed well enough to meet the statistical criteria for non-inferiority to surgery in the PORTICO IDE trial. The company will likely look to its next-generation of Portico for more impressive results.
You may also be interested in...
Abbott enters the highly competitive TAVR market with its newly CE-marked FlexNav delivery system for Portico.
Abbott Laboratories’ medical device businesses grew 10.6% year over year in the third quarter of 2019 while its diagnostics business grew 6.6%, helping the company grow 7.6% overall, the company reported on 16 October.
EuroPCR 2018: Real-World TAVR Data Show Consistent Performance With Edwards, Abbott, And Medtronic's Systems
New real-world data on Edward Lifesciences real-world data for its transcatheter aortic valve replacement Sapien 3 valve are among the highlights from the early Hot Line/Late-Breaking Trial sessions at the EuroPCR conference in Paris.